Edition:
United States

OncoSec Medical Inc (ONCS.OQ)

ONCS.OQ on NASDAQ Stock Exchange Capital Market

1.38USD
18 Jun 2018
Change (% chg)

$-0.08 (-5.48%)
Prev Close
$1.46
Open
$1.45
Day's High
$1.45
Day's Low
$1.38
Volume
58,825
Avg. Vol
148,330
52-wk High
$2.95
52-wk Low
$0.88

Chart for

About

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid... (more)

Overall

Beta: 2.91
Market Cap(Mil.): $75.16
Shares Outstanding(Mil.): 51.48
Dividend: --
Yield (%): --

Financials

  ONCS.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -1.05 -- --
ROI: -127.77 -5.87 13.17
ROE: -133.96 -7.71 15.15

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

May 08 2018

BRIEF-Oncosec Medical Says Board Determined To Consolidate Roles Of CEO And President

* ONCOSEC MEDICAL INC - BOARD DETERMINED TO CONSOLIDATE ROLES OF CHIEF EXECUTIVE OFFICER AND PRESIDENT

May 04 2018

BRIEF-Oncosec Medical Prices $20 Mln Public Offering Of Common Stock

* SAYS PUBLIC OFFERING OF 13.3 MILLION COMMON SHARES PRICED AT $1.50PER SHARE Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-OncoSec Medical Announces Proposed Public Offering Of Common Stock

* ONCOSEC MEDICAL INCORPORATED ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Jan 31 2018

BRIEF-OncoSec Provides Encouraging Clinical Observations Related To Triple Negative Breast Cancer Study

* ONCOSEC PROVIDES ENCOURAGING CLINICAL OBSERVATIONS RELATED TO TRIPLE NEGATIVE BREAST CANCER STUDY Source text for Eikon: Further company coverage:

Jan 18 2018

BRIEF-Oncosec Plans To Conduct A Second Clinical Trial In Triple Negative Breast Cancer In 2018​

* ONCOSEC MEDICAL INC - PLAN TO CONDUCT A SECOND CLINICAL TRIAL IN TRIPLE NEGATIVE BREAST CANCER IN 2018​

Jan 03 2018

Earnings vs. Estimates